microRNA-219-5p targets NEK6 to inhibit hepatocellular carcinoma progression

Gong Ting1, Xin Li2, Hyog Young Kwon3

  • 1Department of Anesthesiology, Shenzhen Hospital of Southern Medical University Shenzhen 518100, China.

Insights

MicroRNA-219-5p acts as a tumor suppressor in liver cancer (HCC). Lower levels of miR-219-5p in HCC patients indicate a higher risk of recurrence after surgery.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • MicroRNA-219-5p (miR-219-5p) is a regulator of gene expression implicated in cancer.
  • Its specific role in hepatocellular carcinoma (HCC) requires further investigation.

Purpose of the Study:

  • To elucidate the function of miR-219-5p in HCC.
  • To identify miR-219-5p as a potential diagnostic biomarker for HCC recurrence.

Main Methods:

  • Quantitative real-time PCR to measure miR-219-5p and NEK6 expression in HCC cells and patient serum.
  • In vitro and in vivo assays to assess the impact of miR-219-5p and NEK6 on HCC cell proliferation, migration, and metastasis.
  • Bioinformatics analysis to correlate miR-219-5p and NEK6 expression with HCC patient data.

Main Results:

  • miR-219-5p expression was significantly decreased in HCC tissues and serum compared to controls.
  • Overexpression of miR-219-5p inhibited HCC cell proliferation, migration, and metastasis.
  • miR-219-5p suppressed NEK6 expression, impacting the β-catenin/c-Myc pathway.
  • Reduced perioperative miR-219-5p levels correlated with increased risk of early HCC recurrence.

Conclusions:

  • miR-219-5p functions as a tumor suppressor in HCC by targeting NEK6.
  • miR-219-5p is a promising diagnostic biomarker for predicting early recurrence in HCC patients post-hepatectomy.